
Regulatory
about 23 hours ago
Pharmaceutical Executive Daily: FDA Approves Cosentyx and WilserdlyLatest Content

White House Withdraws Dr. Heidi Overton’s Nomination as FDA Commissioner: Report

Pfizer, Verismo Strike Licensing Deals to Push CAR T Manufacturing In Vivo

The Workload Balance in Pharma Between Humans and Agentic Models

Pharmaceutical Executive Daily: FDA Approves Cosentyx and Wilserdly

Gilead Signs Royalty-Free Licensing Deals to Broaden Access to Obeldesivir

Shorts









Podcasts
Videos
All News

FDA submitted approvals for Novartis’s Cosentyx and Roche’s Wilserdly.

Agentic AI turns wasted windshield time into productive CRM updates and deploys always-on virtual reps to support providers whenever information is needed.

FDA approves three new therapies, a wave of dealmaking led by Johnson & Johnson, Eli Lilly, AmyriAD Therapeutics, and Sanofi, and Ossium Health’s Kevin Caldwell joins The Ron Lanton Report on rebuilding bone marrow transplants around deceased-donor marrow.

New deals this week span across ophthalmology to Alzheimer’s, with three new acquisitions and one research collaboration.

FDA approves Genentech’s Gazyva, Alexion’s Klygefa, and Teva’s Igalm.

Sustainable competitive advantage requires combining proprietary evidence, AI, and human expertise—not substituting one for another.

Ossium Health’s Kevin Caldwell joins The Ron Lanton Report to explain how banked, deceased-donor marrow is replacing a months-long search for a living donor with a product hospitals can order on demand.

Pharma field forces face three key challenges: scaling services beyond tier one, shifting from reactive to proactive engagement, and empowering teams with agentic AI.

FDA reportedly shelves its Commissioner’s National Priority Voucher program, Eli Lilly breaks ground on a $3.5 billion Pennsylvania manufacturing site for next-generation obesity treatments, and Parexel’s Stacy Hurt on how small protocol decisions can become enrollment and retention barriers.

FDA Commissioner’s National Priority Voucher program reportedly in limbo for expedited drug reviews.

Eli Lilly breaks ground on a $3.5 billion manufacturing facility in Pennsylvania to produce next-generation obesity treatments like retatrutide.

Every protocol decision affects patients, and only those with lived disease experience can identify true burden — from invasive biopsies to daily trial demands.

Moderna lays out an oncology-driven growth plan at its 2026 Analyst Day, Pfizer and Blackstone sign a co-funding deal worth up to $1.5 billion for berobenatide, and Parexel’s Stacy Hurt on how patients’ use of AI is reshaping sponsor communication.

Moderna used its 2026 Analyst Day to outline an oncology-driven growth strategy anchored by intismeran and other cancer antigen therapies.

Pfizer and Blackstone Life Sciences sign a co-funding deal in which Blackstone is set to provide up to $1.5 billion through 2028 to advance berobenatide.





















